Pricey or Priceless: Cost-Effectiveness of Respiratory Syncytial Virus (RSV) Prevention in Infants
- Xiao Li; Joke Bilcke; Philippe Beutels
Access Resources
About
This comment discusses the cost-effectiveness of preventing RSV in infants. It compares different strategies, like using monoclonal antibodies (nirsevimab) and a maternal vaccine (MV). It highlights that while these new methods are promising, they are expensive. The research shows that combining both treatments can be effective and budget-friendly if priced right. However, there are challenges in implementation and some limitations in the study's comparisons. Overall, it emphasizes the importance of understanding costs to make informed healthcare decisions for protecting infants against RSV worldwide.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.